GLP-1 Panel
A GLP-1 lab panel checks glucose control, insulin patterns, lipids, liver and kidney markers, and inflammation to track progress and safety over time.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
This is a bundled lab panel designed for people using (or considering) GLP-1–based medications and lifestyle changes for weight loss, prediabetes, or type 2 diabetes. Instead of a single number, you get a set of results that can explain why weight loss stalls, why your A1c and finger-stick glucose don’t match, and whether your cardiometabolic risk markers are moving in the right direction.
Because GLP-1 therapy affects appetite, weight, glucose, and sometimes lipids and liver enzymes, it helps to monitor more than just A1c. This panel is built to show the bigger picture so you and your clinician can make safer, more confident decisions about dosing, nutrition, training, and follow-up timing.
Do I need this panel?
You may benefit from a GLP-1 panel if you are using an incretin medication (such as semaglutide or tirzepatide) and you want to track both effectiveness and safety in one blood draw. Many people feel better and lose weight quickly at first, then hit a plateau. A panel can help you see whether the plateau is more likely related to glucose/insulin patterns, calorie intake dropping too low, loss of lean mass, changes in thyroid signaling, or a mismatch between short-term glucose and longer-term A1c.
This panel is also useful if your A1c and your day-to-day glucose readings don’t seem to agree. A1c reflects average blood sugar over roughly 2–3 months, while fasting glucose and insulin reflect what is happening right now. Looking at them together can clarify whether you are improving, stuck, or possibly experiencing low glucose risk from over-treatment.
You may also want this panel if you have prediabetes or type 2 diabetes and you are trying to reduce cardiovascular risk at the same time. GLP-1 therapy can improve triglycerides and other lipid markers for some people, but not everyone. Checking lipids, inflammation, liver enzymes, and kidney function helps you avoid focusing on weight alone.
This panel supports clinician-directed care and shared decision-making. It is not meant to diagnose conditions by itself, and any medication changes should be made with your prescribing clinician.
This panel includes common blood-based assays; reference ranges and optimal targets can vary by lab method, your medical history, and whether you are on glucose-lowering medications.
Lab testing
Order the GLP-1 Panel and track your progress over time
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault lets you order this GLP-1 lab panel so you can track multiple cardiometabolic markers together—without having to piece results together from separate orders. One draw can cover glucose control, insulin dynamics, lipids, and organ-function markers that matter when appetite and body weight are changing.
After you get results, you can use PocketMD to put the numbers into context: what changed since your last test, which markers tend to move early versus late, and which patterns are more consistent with under-fueling, insulin resistance, medication effects, or missed cardiovascular risk.
If you are adjusting dose, changing training, or trying to preserve muscle while losing fat, trending the same panel over time can be more informative than chasing a single “perfect” value. You can also use this panel as a baseline before starting therapy and then retest after a consistent interval to see your true response.
- One order, one draw: multiple markers interpreted together
- Designed for trending over time while therapy and lifestyle change
- PocketMD support for pattern-based interpretation and next-step questions
Key benefits of the GLP-1 Panel
- Shows short-term glucose (fasting glucose) alongside longer-term control (A1c) so you can spot mismatches.
- Adds fasting insulin and insulin-resistance estimates to explain why weight loss or energy can stall even when appetite is lower.
- Tracks lipid changes (LDL-C, HDL-C, triglycerides, ApoB) to keep cardiovascular risk in view, not just the scale.
- Monitors liver enzymes and metabolic-liver signals that can shift with rapid weight loss or fatty liver improvement.
- Checks kidney function and electrolytes to support safer medication use and hydration planning.
- Flags patterns consistent with under-fueling or lean-mass loss risk (for example, low protein status signals alongside aggressive calorie restriction).
- Creates a consistent baseline and retest framework so you can evaluate dose changes, nutrition shifts, and training updates with fewer guesses.
What is the GLP-1 panel?
The GLP-1 panel is a bundled set of blood tests that helps you monitor cardiometabolic health while using GLP-1–based therapy (or while pursuing similar goals through lifestyle changes). GLP-1 medications can reduce appetite and improve glucose control, but your response is individual. Some people see major A1c improvements with modest lipid changes; others see the opposite. A panel approach helps you interpret results as a system.
In practical terms, this panel groups markers into a few categories:
• Glucose control over time and in the moment: Hemoglobin A1c (HbA1c) and fasting glucose. • Insulin dynamics: fasting insulin and derived estimates such as HOMA-IR, which can help explain insulin resistance patterns. • Cardiovascular risk: cholesterol fractions and particle-related markers (such as ApoB) that can remain elevated even when weight is dropping. • Safety and organ function: liver enzymes, kidney markers, and electrolytes that can change with dehydration, rapid weight loss, or medication side effects. • Inflammation and metabolic context: markers like hs-CRP that can reflect systemic inflammation and cardiometabolic risk.
This panel does not measure the medication itself or GLP-1 hormone levels. Instead, it measures the downstream physiology you are trying to improve (and the organ systems you want to monitor) so you can make more informed choices about dosing, nutrition, activity, and follow-up timing.
What do my panel results mean?
Low (or lower-than-expected) patterns on this panel
A “low” pattern depends on which section of the panel is low. If A1c and fasting glucose are very low—especially if you use insulin, sulfonylureas, or multiple glucose-lowering agents—this can raise concern for over-treatment or hypoglycemia risk, even if you feel fine. If fasting insulin is very low while glucose is normal, it may reflect improved insulin sensitivity, but in some cases it can also occur with under-fueling, prolonged fasting, or significant calorie restriction. Low triglycerides and improving hs-CRP often align with better metabolic health, but if multiple nutrition-related markers trend down at the same time (for example, low total protein/albumin alongside rapid weight loss), it can be a sign to prioritize adequate protein and resistance training to protect lean mass.
Optimal patterns on this panel
An “optimal” panel pattern usually looks like consistent glucose control (A1c moving toward your clinician-set target and fasting glucose in a stable range), with fasting insulin and HOMA-IR trending down over time. Lipids often show lower triglycerides, higher or stable HDL-C, and improving ApoB/LDL-related markers—though lipid response can lag behind weight changes. Liver enzymes that are normalizing (or staying normal) and stable kidney function support that your current approach is working without obvious organ stress. The most helpful sign is alignment: multiple categories improving together rather than one number improving while others worsen.
High (or higher-risk) patterns on this panel
A “high” pattern can show up as persistent elevation in A1c and fasting glucose, often paired with higher fasting insulin or HOMA-IR—suggesting ongoing insulin resistance or inadequate therapy response. Some people see A1c improve while fasting glucose remains high (or vice versa); that mismatch can point to dawn phenomenon, variable post-meal spikes, anemia-related A1c distortion, or inconsistent medication timing. Cardiovascular risk can remain higher than expected if ApoB or LDL-related markers stay elevated even with weight loss, which is why lipids are included. Elevated liver enzymes may reflect fatty liver, medication effects, alcohol, supplements, or rapid weight loss; kidney markers and electrolytes can rise with dehydration, vomiting, or inadequate fluid intake—issues that can occur with GLP-1 side effects.
Factors that influence GLP-1 panel markers
Your results are influenced by timing, medications, and recent behavior. Fasting duration, recent exercise, sleep, stress, and illness can shift glucose and insulin. GLP-1 dose changes, missed doses, and other diabetes medications can change A1c and fasting glucose trends; steroid medications can raise glucose and worsen insulin resistance. Rapid weight loss and reduced intake can change lipids and liver enzymes in either direction in the short term, and dehydration can concentrate kidney markers and alter electrolytes. A1c can be misleading in conditions that affect red blood cell turnover (such as anemia or recent blood loss). The most reliable interpretation comes from looking at the pattern across categories and comparing to your prior results, not from a single isolated value.
What’s included in this panel
- Absolute Band Neutrophils
- Absolute Basophils
- Absolute Blasts
- Absolute Eosinophils
- Absolute Lymphocytes
- Absolute Metamyelocytes
- Absolute Monocytes
- Absolute Myelocytes
- Absolute Neutrophils
- Absolute Nucleated Rbc
- Absolute Plasma Cells
- Absolute Prolymphocytes
- Absolute Promyelocytes
- Absolute Reactive Lymphocytes
- Albumin
- Albumin/Globulin Ratio
- Alkaline Phosphatase
- Alt
- Amylase
- Ast
- Band Neutrophils
- Basophils
- Bilirubin, Total
- Blasts
- Bun/Creatinine Ratio
- Calcium
- Carbon Dioxide
- Chloride
- Chol/Hdlc Ratio
- Cholesterol, Total
- Creatinine
- Dhea Sulfate
- Egfr
- Eosinophils
- Estradiol
- Ferritin
- Folate, Serum
- Globulin
- Glucose
- Hdl Cholesterol
- Hdl Large
- Hematocrit
- Hemoglobin
- Hemoglobin A1C
- Insulin
- Iron Binding Capacity
- Iron, Total
- Ldl-Cholesterol
- Ldl/Hdl Ratio
- Ldl Medium
- Ldl Particle Number
- Ldl Pattern
- Ldl Peak Size
- Ldl Small
- Lipase
- Lymphocytes
- Magnesium
- Mch
- Mchc
- Mcv
- Metamyelocytes
- Monocytes
- Mpv
- Myelocytes
- Neutrophils
- Non Hdl Cholesterol
- Nucleated Rbc
- Phosphate (As Phosphorus)
- Plasma Cells
- Platelet Count
- Potassium
- Progesterone
- Prolymphocytes
- Promyelocytes
- Protein, Total
- Rdw
- Reactive Lymphocytes
- Red Blood Cell Count
- % Saturation
- Sex Hormone Binding Globulin
- Sodium
- T3, Free
- T4, Free
- Testosterone, Free
- Testosterone, Total, Ms
- Triglycerides
- Tsh
- Urea Nitrogen (Bun)
- Vitamin B12
- Vitamin D, 25-Oh, D2
- Vitamin D, 25-Oh, D3
- Vitamin D, 25-Oh, Total
- White Blood Cell Count
Frequently Asked Questions
Do I need to fast for the GLP-1 panel?
Fasting is usually helpful for the insulin and fasting glucose portions of the panel, and it can make triglycerides easier to interpret. Follow the instructions provided with your order and ask your clinician if you have diabetes medications that could increase low-glucose risk during fasting.
How often should I repeat this panel while on a GLP-1 medication?
Many people retest after a stable period on a new dose or routine so changes are easier to attribute—often around 8–12 weeks for A1c trends. If you are having side effects, changing multiple medications, or monitoring kidney/liver markers closely, your clinician may recommend earlier follow-up.
Why can my A1c improve while my fasting glucose is still high (or the opposite)?
A1c reflects an average over time, while fasting glucose is a single point in time and is sensitive to sleep, stress, illness, and the dawn phenomenon. A mismatch can also occur if A1c is distorted by anemia or changes in red blood cell turnover. Looking at both values together, plus fasting insulin, often clarifies the story.
Does this panel tell me if my GLP-1 dose is “right”?
No single lab panel can determine the perfect dose. Your dose is a clinical decision based on symptoms, side effects, weight trajectory, glucose targets, and risk factors. This panel helps by showing whether glucose control, insulin resistance, lipids, and organ-function markers are trending in the direction you and your clinician want.
I’m losing weight but worried about muscle loss. Can this panel help?
It can provide indirect clues. Rapid weight loss paired with signs of under-fueling (for example, low-normal protein status markers) may support a conversation about protein intake and resistance training. For a more direct muscle assessment, you may also consider body composition tracking and nutrition review alongside labs.
Is it better to order this panel or order A1c and glucose alone?
If you only need a quick check of glycemic control, a focused A1c/glucose order may be enough. If you want a broader view—especially if you are adjusting therapy, dealing with plateaus, or tracking cardiovascular risk—this panel can be more efficient because it interprets multiple related systems together.
What should I do if my lipids or ApoB are still high even though I’m on a GLP-1?
Bring the full lipid pattern (including ApoB if available) to your clinician. Some people need additional dietary changes, more time, or separate lipid-lowering therapy depending on risk. The key is not to assume weight loss automatically equals optimal cardiovascular risk.